Clinical Trials Logo

Clinical Trial Summary

In this study we want to show that the choice of a balanced type fluid solution for the perioperative fluid management of patients receiving cadaveric renal transplantation results in less occurrence of intra- and postoperative hyperkalemia, and thus the need for postoperative dialysis. Additionally, we aim to determine whether the use of a balanced infusion solution leads to less occurrence of metabolic acidosis and electrolyte disorders than the use of isotonic saline.

Furthermore we want to evaluate whether perioperative fluid management with balanced infusion solutions results in a higher frequency of primary graft function than with administration of isotonic saline.

We will test the hypothesis that the use of "Elomel isoton"(Fresenius Kabi Austria GmbH) a balanced infusion solution will result in less occurrence of hyperkalemia and consequent post-transplant dialysis, less occurrence of metabolic acidosis, decreased incidence of electrolyte disorders and higher incidence of primary graft function when compared to isotonic saline for perioperative fluid management in patients receiving cadaveric renal transplantation.


Clinical Trial Description

Background

Kidney transplantation is the treatment of choice for patients with end-stage-renal-disease (ESRD). Successful renal transplantation improves quality of life and reduces mortality in eligible patients when compared to hemodialysis. In 2007, 44 kidney transplantations per million residents were performed in Austria. The number of patients with a renal transplant has continuously risen in the last ten years. 398 kidney transplantations were performed in Austria in 2007, of which only 61 were of living donors. This underlines the special role of cadaveric kidney transplantation in Austria.

Several studies have demonstrated that adequate intraoperative fluid administration is associated with earlier onset of graft function and improved graft survival in renal transplant recipients. However, which kind of solution should be chosen for the perioperative fluid management of renal transplant recipients remains to be clarified. A non-governmental US survey has shown that normal saline is the most commonly used fluid for renal transplantation. The most common cited reason for the administration of normal saline was the lack of potassium in the solution. Balanced salt type fluids were used in only less than 10% of kidney transplantations.

To our knowledge only three studies compared the effects of lactated ringer's solution versus normal saline in kidney transplantation. Taken together, the application of lactated ringer's solution led to less occurrence of metabolic acidosis, electrolyte derangements and in one study, the appearance of hyperkalemia was eliminated by the use of lactated ringer's instead of normal saline. However, it was also shown that the administration of lactated ringer's during kidney transplantation led to a significant rise in lactate levels compared to those treated with normal salin. Despite the knowledge that lactated ringer's can at least potentially lead to a rise in lactate levels, no studies using acetate based balanced salt type fluids have been performed so far in cadaveric renal transplantation. We therefore propose a prospective study in which patients undergoing cadaveric kidney transplantation will be randomized to receive either a solely acetate buffered balanced salt type fluid or a normal saline for infusion therapy.

Clinical considerations

Postoperative hyperkalemia is a common problem in patients receiving cadaveric renal transplantation, especially when primary graft function does not occur. Due to the acidifying effect of isotonic saline infusion via the generation of hyperchloremic acidosis and/or dilutional acidosis, a rise in serum potassium is only boosted. However, today isotonic saline is the most commonly used infusion solution for the perioperative period in renal transplantation.

The use of a balanced infusion solution, containing a metabolizable anion, such as acetate, could result in less metabolic acidosis and therefore a decreased need for post-transplant dialysis. Moreover, since balanced infusion solutions have a by far lower chloride content than isotonic saline, the adverse effects of a rise in serum chloride on renal perfusion could be avoided. This could ultimately result in improved graft function.

Preliminary studies

O'Malley et al. compared the effects of lactated Ringer's to isotonic saline in 51 renal transplant patients. 48 patients received living donor transplantation and 3 received cadaveric renal transplantation. 26 patients received isotonic saline and 25 lactated Ringer's. 19% of patients receiving isotonic saline reached postassium concentrations > 6mmol/L and required treatment versus 0% in the lactated Ringer's group. 31% of patients in the isotonic saline group versus 0% in the lactated Ringer's group required treatment for metabolic acidosis. No effect on primary graft function could be shown.

Hadimioglu et al. randomized patients undergoing living-related kidney transplantation to three groups receiving either isotonic saline, lactated Ringer's or Plasmalyte (a balanced infusion solution using acetate and gluconate). No effects on potassium levels could be shown in this study. Patients receiving isotonic saline showed significant decreases in pH, base excess and a significant rises in serum chloride. In the lactated Ringer's group lactate levels increased significantly. The study showed no differences in the need for postoperative dialysis.

Khajavi et al. randomized patients undergoing kidney transplantation to either normal saline or lactated Ringer's. The authors noticed a higher incidence of hyperkalemia and acidosis in the isotonic saline group while 2 patients in the lactated Ringer's group lost their kidneys due to vascular graft thrombosis. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01075750
Study type Observational
Source Medical University of Vienna
Contact
Status Completed
Phase N/A
Start date June 2010
Completion date February 2013

See also
  Status Clinical Trial Phase
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Completed NCT03317444 - Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease Phase 3
Recruiting NCT05582824 - Lactate Metabolism in the Hypoperfused Critically Ill
Active, not recruiting NCT04010630 - Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in ICU N/A
Completed NCT02303548 - Bicarbonate in Patients With Out-of-hospital Cardiac Arrest Phase 2
Recruiting NCT01860001 - Incidence of Postoperative Ketosis and Metabolic Acidosis N/A
Completed NCT01452412 - Alkali Therapy in Chronic Kidney Disease Phase 2/Phase 3
Terminated NCT03710291 - Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis Phase 3
Recruiting NCT02476253 - Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill Phase 3
Completed NCT05940935 - The Relationship of Developing Metabolic Acidosis With Antiepleptic Drugs in Craniotomy Operations
Withdrawn NCT03846258 - High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy Phase 4
Completed NCT05970094 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Recruiting NCT05784389 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Terminated NCT04727528 - Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease Phase 3
Completed NCT02098356 - Comparison of High Versus Low Bicarbonate Hemodialysis N/A
Recruiting NCT03897101 - Inflammation and Metabolic Acidosis at Birth (AGAIN: AutophaGy AcIdosis Newborn)
Terminated NCT01894594 - Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease Phase 1
Completed NCT01293266 - Effect of Propofol and Sevoflurane on Lactate During Anesthesia for Pediatric Heart Catheterisation N/A
Completed NCT01295190 - Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass N/A
Completed NCT05147051 - Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients Phase 2